


IN THE CLAIMS


Please amend the claims as follows:

Claim 1 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:



wherein,


- $R_2$  and  $R_3$ , which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro (proline) residue, and


- $R_5$  represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 2 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof a phosphinic pseudopeptide derivative corresponding to formula (II) below:



wherein,

- $\text{R}_1$  represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $\text{R}_2$  and  $\text{R}_3$ , which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,


- $\text{R}_4$  represents a hydrogen atom or a pharmacologically acceptable counterion, and
- $\text{R}_5$  represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 3 (Previously Presented): The method of Claim 2, wherein  $\text{R}_1$  represents a protecting group for an amine function chosen from acetyl and benzyloxycarbonyl groups.

Claim 4 (Previously Presented): The method of Claim 1, wherein  $\text{R}_2$  represents the benzyl, methyl or phenylethyl group.


Claim 5 (Previously Presented): The method of Claim 1, wherein R<sub>3</sub> represents the side chain of alanine, arginine or tryptophan.

Claim 6 (Previously Presented): The method of Claim 1, wherein the sequence –NH-CH(R<sub>3</sub>)-CO- forms the Pro residue:




Claim 7 (Currently Amended): The method of Claim 1, wherein R<sub>4</sub> and/or R<sub>5</sub> represent(s) a hydrogen atom.

Claim 8 (Previously Presented): The method of Claim 2, wherein the phosphinic pseudopeptide derivative is:




(pseudo-peptide G)

Claim 9 (Previously Presented): A phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I):




wherein,

- $R_2$  represents the side chain of a natural or unnatural amino acid,
- the sequence:




forms the Pro residue:



and


- $R_5$  represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 10 (Previously Presented): A phosphinic pseudopeptide derivative of formula (II):




wherein,

- $R_1$  represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$  represents the side chain of a natural or unnatural amino acid,
- the sequence:




forms the Pro residue:



- $R_4$  represents a hydrogen atom or a pharmacologically acceptable counterion, and
- $R_5$  represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.


Claim 11 (Previously Presented): A phosphinic pseudopeptide derivative of formula:



(pseudo-peptide G)


Claim 12 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 9.

Claim 13 (Previously Presented): A pharmaceutical composition, comprising a phosphinic pseudopeptide derivative of formula:




(pseudo-peptide G)

Claim 14 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein:

- $R_1$  represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$  and  $R_3$ , which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue, and


- $\text{R}_4$  and  $\text{R}_5$  represent a hydrogen atom;

which comprises the following steps:


- 1) reacting a compound of formula (III):




in which  $\text{R}_1$  and  $\text{R}_2$  are as defined above, with the compound of formula (IV):




in which Ac represents the acetyl group and Et represents the ethyl group, to obtain the compound of formula (V):




2) converting compound (V) into compound (VI) by reacting compound (V) with sodium borohydride:




3) protecting the hydroxyl group of compound (VI) with a protecting group R5 to give the compound of formula (VII):



4) saponifying compound (VII) to give the compound of formula (VIII):



5) coupling the compound of formula (VIII) with the amino acid of formula (IX) or (X):




in which R3 is as defined above, and

6) removing the protecting group R5.


Claim 15 (Previously Presented): A process as claimed in Claim 14, wherein the peptide coupling step 5) is performed via solid-phase peptide synthesis wherein the solid phase is a resin substituted with the amino acid of formula (IX) or (X).

Claim 16 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein,

- $R_1$  represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$  and  $R_3$ , which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue,

- $R_4$  represents a hydrogen atom, and
- $R_5$  represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of Claim 14 is esterified by coupling with an alcohol of formula  $R_5OH$  or by reaction with a halide of formula  $R_5X$  in which X represents a halogen atom.

Claim 17 (Previously Presented): A compound of formula (VIII):




wherein:

- Ad represents an adamantyl group,
- $R_1$  represents a protecting group for an amine function or an amino acid or a peptide protected with an amine function, and
- $R_2$  represents the side chain of a natural or unnatural amino acid.

Claim 18 (Previously Presented): The method of Claim 2, wherein  $R_2$  represents the benzyl, methyl or phenylethyl group.

Claim 19 (Previously Presented): The method of Claim 2, wherein  $R_3$  represents the side chain of alanine, arginine or tryptophan.

Claim 20 (Previously Presented): The method of Claim 2, wherein the sequence –  $NH-CH(R_3)-CO-$  forms the Pro residue:




Claim 21 (Previously Presented): The method of Claim 2, wherein R<sub>4</sub> and/or R<sub>5</sub> represent(s) a hydrogen atom.

Claim 22 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 10.


Claim 23 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 11.

Claim 24 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein,

- R<sub>1</sub> represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R<sub>2</sub> and R<sub>3</sub>, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,

- R<sub>4</sub> represents a hydrogen atom, and
- R<sub>5</sub> represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of  
Claim 15 is esterified by coupling with an alcohol of formula R<sub>5</sub>OH or by reaction with a  
halide of formula R<sub>5</sub>X in which X represents a halogen atom.

Claim 25 (Previously Presented): A process as claimed in Claim 14, wherein R<sup>5</sup> is an  
adamantly group.